Research

Hormonal

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GLP-1/GIP agonists (tirzepatide) are the most promising pharmacological treatments for obesity in older adults, offering favorable efficacy and safety profiles, though specific guidelines are currently lacking.

For older adults with obesity, GLP-1 agonists like liraglutide and semaglutide are currently the most effective pharmacological options. They work by mimicking hormones that regulate appetite and blood sugar. While they cause significant weight loss, there is a risk of muscle loss, so these medications should ideally be used alongside resistance exercise and adequate protein intake. Start with a low dose and increase slowly to manage stomach side effects. Note that data for those over 75 is limited.

ModerateSupportsMEDIUM confidence
From currently available obesity pharmacotherapy, GLP-1 agonist (or combined GLP-1 and GIP agonist) data offer the most promising weight loss, body composition and safety outcomes in older adults; however, more research on muscle/bone mass preservation is needed.
Ondřej Žižka et al. · Drugs & Aging · 2024

Why this rating

Based on post-hoc analyses of large trials (SCALE, SUSTAIN, LEADER) and small specific trials, but lacking dedicated large-scale RCTs for >65s.

Source

Pharmacological Treatment of Obesity in Older Adults

Ondřej Žižka et al. · Drugs & Aging · 2024

DOI 10.1007/s40266-024-01150-9

narrative_reviewCited 16×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →